Clinical Trial Update: Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Suberoylanilide Hydroxamic Acid in recurrent or advanced non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Suberoylanilide Hydroxamic Acid (Suberoylanilide Hydroxamic Acid)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-05-21